Salix Pharmaceuticals (NASDAQ:SLXP) is kicking off 2014 with a bigger sales team carrying big expectations following the company’s $2.8 billion acquisition of Santarus – expectations that pushed the ...
Valeant’s plans to sell its Salix subsidiary to Japan’s Takeda are in disarray after negotiations fell apart at a late stage, according to reports. Citing unnamed sources, the Wall Street Journal says ...
Valeant Pharmaceuticals International Inc.'s proposed acquisition of Salix Pharmaceuticals Ltd. and another recent deal position the company to expand in two new high-growth therapeutic areas, Valeant ...
Valeant needs to sell assets to unlock value for shareholders. Takeda needs Salix because its organic growth is declining rapidly. Salix also fits in well with Takeda's other properties. The Salix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback